Company Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.81 USD | -0.76% |
|
-7.45% | -26.02% |
| 03-05 | Profound Medical Corp. Announces Board Changes, Effective March 5, 2026 | CI |
| 03-04 | China Merchants Initiates Boston Scientific at Buy With $88 Price Target | MT |
Business description: Boston Scientific Corporation
- cardiovascular (66%): products used in cardiology surgeries (35% of net sales), electrophysiology tests (25.1%) cardiac rhythm management (17.6%), peripheral surgeries (7.5%), and other (14.8%);
- endodontic surgery (28%): equipment used in endoscopy (51.8% of net sales), and urology (48.2%) ;
- neuromodulation (6%).
Net sales are distributed geographically as follows: the United States (64.1%), Europe/Middle East/Africa (17.2%), Asia/Pacific (15.4%) and other (3.3%).
Number of employees: 59,000
Sales by Activity: Boston Scientific Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Cardiovascular (Incl. Rhythm) | 4.86B | 7.83B | 8.82B | 10.76B | 13.25B |
MedSurg | 3.72B | 4.91B | 5.42B | 5.99B | 6.82B |
Rhythm and Neuro | 3.29B | - | - | - | - |
Specialty Pharmaceuticals | 13M | - | - | - | - |
Other | - | -60M | - | - | - |
Geographical breakdown of sales: Boston Scientific Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States (U.S.) | 6.91B | 7.63B | 8.42B | 10.21B | 12.86B |
Europe, Middle East and Africa (EMEA) | 2.52B | 2.53B | 2.86B | 3.23B | 3.45B |
Asia-Pacific (APAC) | 2.07B | 2.12B | 2.4B | 2.69B | 3.08B |
Latin America and Canada (LACA) | 386M | 469M | 560M | 624M | 678M |
International | 4M | - | - | - | - |
Other Countries | - | -60M | - | - | - |
Executive Committee: Boston Scientific Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Mahoney
CEO | Chief Executive Officer | 61 | 31/10/2011 |
Jonathan Monson
DFI | Director of Finance/CFO | 52 | 29/06/2025 |
John Sorenson
COO | Chief Operating Officer | 58 | 30/04/2022 |
Kenneth Stein
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/2009 |
Charlie Attlan
PRN | Corporate Officer/Principal | - | 28/02/2010 |
Composition of the Board of Directors: Boston Scientific Corporation
| Director | Title | Age | Since |
|---|---|---|---|
John Sununu
BRD | Director/Board Member | 61 | 31/03/2009 |
Michael Mahoney
CHM | Chairman | 61 | 02/05/2016 |
Edward Ludwig
BRD | Director/Board Member | 74 | 28/02/2014 |
Ellen Zane
BRD | Director/Board Member | 74 | 14/04/2016 |
| Director/Board Member | 73 | 12/07/2016 | |
David Wichmann
BRD | Director/Board Member | 63 | 22/06/2021 |
Jessica Mega
BRD | Director/Board Member | 51 | 26/06/2023 |
Susan Morano
BRD | Director/Board Member | - | 26/06/2023 |
Cheryl Pegus
BRD | Director/Board Member | 62 | 07/05/2024 |
Dave Habiger
BRD | Director/Board Member | 57 | 29/07/2024 |
Holdings: Boston Scientific Corporation
| Name | Equities | % | Valuation |
|---|---|---|---|
| 203,702,962 | 65% | 360 M $ | |
M.I.TECH CO.,LTD 9.83% | 3,180,000 | 9.83% | 17 M $ |
Company details: Boston Scientific Corporation
Boston Scientific Corp.
300 Boston Scientific Way
01752-1234, Marlborough
+508 683 4000
http://www.bostonscientific.com
Group companies: Boston Scientific Corporation
| Name | Category and Sector |
|---|---|
Boston Scientific India Pvt Ltd.
 Boston Scientific India Pvt Ltd. Medical SpecialtiesHealth Technology Manufactures and supplies medical devices & equipment |
Medical Specialties
|
Boston Scientific India Pvt Ltd.
Boston Scientific India Pvt Ltd. Medical SpecialtiesHealth Technology Manufactures and supplies medical devices & equipment |
Medical Specialties
|
Boston Scientific Technology & Engineering Services Pvt Ltd. | |
Boston Scientific Technology & Engineering Services Pvt Ltd. | |
Boston Scientific Asia Pacific Pte Ltd. |
Other Advanced Medical Equipment & Technology
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.76% | -7.45% | -25.06% | +49.89% | 106B | |
| -0.50% | -2.60% | -5.97% | -10.46% | 186B | |
| -1.27% | -2.42% | +0.34% | +111.85% | 174B | |
| +0.20% | -5.40% | -5.05% | -20.01% | 138B | |
| -1.37% | -3.99% | -23.53% | -22.33% | 52.29B | |
| +0.56% | -6.06% | +19.50% | +7.71% | 47.42B | |
| -0.67% | -3.12% | +5.38% | +17.55% | 36.67B | |
| -0.40% | -8.26% | -13.85% | -3.72% | 33.85B | |
| -0.25% | -3.49% | -6.44% | -17.91% | 32.52B | |
| +2.93% | -2.45% | -25.69% | -40.75% | 31.81B | |
| Average | -0.16% | -5.00% | -8.04% | +7.18% | 83.92B | |
| Weighted average by Cap. | -0.43% | -4.81% | -7.16% | +21.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSX Stock
- Company Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition